These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 2746366)
21. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN. Visser GW; Klok RP; Gebbinck JW; ter Linden T; van Dongen GA; Molthoff CF J Nucl Med; 2001 Mar; 42(3):509-19. PubMed ID: 11337531 [TBL] [Abstract][Full Text] [Related]
22. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model. Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357 [TBL] [Abstract][Full Text] [Related]
23. [Preparation of 125I-labelled monoclonal antibodies of the insulin receptor]. Sesti G; Marini MA; Montemurro A; Di Daniele N; Bertoli A; Cordera R; Andraghetti G; De Pirro R; Lauro R; Monaco F C R Seances Soc Biol Fil; 1988; 182(2):167-76. PubMed ID: 2973824 [TBL] [Abstract][Full Text] [Related]
25. Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate. Vaidyanathan G; Affleck DJ; Zalutsky MR Bioconjug Chem; 1997; 8(5):724-9. PubMed ID: 9327137 [TBL] [Abstract][Full Text] [Related]
26. Developments in techniques for radioiodination of peptide hormones and other proteins. Karonen SL Scand J Clin Lab Invest Suppl; 1990; 201():135-8. PubMed ID: 2244182 [TBL] [Abstract][Full Text] [Related]
27. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303 [TBL] [Abstract][Full Text] [Related]
29. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Stein R; Goldenberg DM; Thorpe SR; Basu A; Mattes MJ Cancer Res; 1995 Jul; 55(14):3132-9. PubMed ID: 7606734 [TBL] [Abstract][Full Text] [Related]
30. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer. Boerman OC; Tibben JG; Massuger LF; Claessens RA; Corstens FH Anticancer Res; 1995; 15(5B):2169-74. PubMed ID: 8572619 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989 [TBL] [Abstract][Full Text] [Related]
32. A facile no-carrier-added radioiodination procedure suitable for radiolabeling kits. Kabalka GW; Mereddy AR Nucl Med Biol; 2004 Oct; 31(7):935-8. PubMed ID: 15464395 [TBL] [Abstract][Full Text] [Related]
33. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657 [TBL] [Abstract][Full Text] [Related]
34. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Reist CJ; Archer GE; Kurpad SN; Wikstrand CJ; Vaidyanathan G; Willingham MC; Moscatello DK; Wong AJ; Bigner DD; Zalutsky MR Cancer Res; 1995 Oct; 55(19):4375-82. PubMed ID: 7671250 [TBL] [Abstract][Full Text] [Related]
35. Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Göttingen/Marburg experience. Behr TM; Gotthardt M; Becker W; Béhé M Nuklearmedizin; 2002 Apr; 41(2):71-9. PubMed ID: 11989301 [TBL] [Abstract][Full Text] [Related]
36. Targeting strategies for cancer radiotherapy. Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. Shankar S; Vaidyanathan G; Affleck DJ; Peixoto K; Bigner DD; Zalutsky MR Nucl Med Biol; 2004 Oct; 31(7):909-19. PubMed ID: 15464393 [TBL] [Abstract][Full Text] [Related]
38. High-level iodination of monoclonal antibody fragments for radiotherapy. Ferens JM; Krohn KA; Beaumier PL; Brown JP; Hellström I; Hellström KE; Carrasquillo JA; Larson SM J Nucl Med; 1984 Mar; 25(3):367-70. PubMed ID: 6699726 [TBL] [Abstract][Full Text] [Related]
39. Development of 3-iodophenylisothiocyanate for radioiodination of monoclonal antibodies. Ram S; Buchsbaum DJ Int J Rad Appl Instrum A; 1992 Nov; 43(11):1387-91. PubMed ID: 1333460 [TBL] [Abstract][Full Text] [Related]
40. Methods for radiolabelling of monoclonal antibodies. Tolmachev V; Orlova A; Andersson K Methods Mol Biol; 2014; 1060():309-30. PubMed ID: 24037848 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]